Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial
Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...
Drug
Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...
Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC
Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...
Hengrui Pharmaceuticals Gets NMPA Approval for Clinical Study of CDK 4/6 Inhibitor Combo in Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
3SBio Secures NMPA Approval for Pediatric Thrombopoietin Treatment of ITP
3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that it...
AbbVie’s Aquipta/Qulipta Shows Promise in Migraine Prevention Trial
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, last week released interim results from a...
Laekna’s Anti-ActRIIA Antibody LAE102 Clears FDA Hurdle for Obesity Treatment Trial
Sino-American biotech firm Laekna has announced that it has received clinical trial approval from the...
AstraZeneca’s Fasenra Gains FDA Approval for Pediatric Severe Asthma Treatment
AstraZeneca (AZ; NASDAQ: AZN) has secured an indication extension from the U.S. Food and Drug...
Qilu Pharmaceutical Gets NMPA Green Light for Generic Romiplostim for ITP Treatment
The National Medical Products Administration (NMPA) in China has granted marketing approval to Qilu Pharmaceutical...
Suzhou Zelgen Receives NMPA Approval for Jacktinib Cream Trial in Vitiligo Patients
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval from...
Haisco Pharmaceutical Gets NMPA Green Light for HSK31858 COPD Trial
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...
Teva’s Ajovy Achieves Positive Results in Phase III Migraine Prevention Trial in China
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has announced positive results from a...
Enhertu Shows 58.3% Response Rate in Phase II Lung Cancer Study, AstraZeneca and Daiichi Sankyo Report
The Phase II DESTINY-Lung05 study results for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate co-developed by...
Yantai Dongcheng Secures Approval for Phase I Study of 68Ga-LNC1007 in Singapor
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has received approval from the Health Sciences...
Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024
Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...
Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu
Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC)...
Pfizer Reports Positive Phase III Results for RSV Vaccine Abrysvo in Younger Adults
Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory...
Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...
Simcere Pharmaceutical’s SIM0500 Earns FDA Fast-Track Designation for Multiple Myeloma
Simcere Pharmaceutical Group (HKG: 2096), a leading China-based pharmaceutical company, has announced that its trispecific...
Roche’s Inavolisib Earns Priority Review Status in China for PIK3CA-Mutated Breast Cancer
Swiss pharmaceutical giant Roche (SWX: ROG) has received priority review status from China’s Center for...